Drug Repurposing in Oncology Therapy: Applications and Challenges

  • 雨萌 王
Expand
  • 1.School of Public Health, Shandong Second Medical University, Shandong Weifang 261000, China;
    2.Medical Information Data Office, the 960th Hospital of the Joint Logistics Support Force of the People's Liberation Army,Shandong Jinan 250031, China

Received date: 2025-05-16

  Revised date: 2026-05-20

  Accepted date: 2026-06-28

  Online published: 2026-10-09

Abstract

The traditional treatment of malignant tumors has long been challenged by inadequate efficacy, frequent drug resistance, and severe toxic side effects. Drug repurposing, an innovative strategy characterized by “short cycle, low cost, and low risk,” provides a novel approach to cancer therapy by systematically exploring new indications for approved drugs. Drug repurposing has unique clinical value in expanding therapeutic diversity, enabling individualized precision therapy, delaying drug resistance, and reducing treatment costs. This study reviews the potential advantages, the mechanisms of action, the clinical progress,the application and translation challenges of drug repurposing in oncology therapy,to provide a systematic reference for future research and clinical translation of drug repurposing. From the perspective of practical applications, the therapeutic practices and mechanisms of antiviral drugs, antidepressants, and immunomodulators in various tumors are systematically reviewed. In terms of the mechanisms of action, this study focuses on the inhibitory effects of repurposed drugs on cancer stem cells, their regulatory effects on the tumor microenvironment, and the progress in discovering and validating new targets through computational biology and artificial intelligence. Regarding clinical advances, the major directions of current clinical trials are outlined, and successful cases such as metformin and niclosamide are analyzed for their clinical translational potential. Meanwhile, challenges remain in clinical trial design, fundamental theoretical exploration, and ethical review. Looking ahead, the integration of precision medicine concepts and advances in big data and artificial intelligence will further drive drug repurposing. However, issues such as intellectual property protection, policy refinement, and bottlenecks in data and models still need to be addressed collaboratively.


Cite this article

雨萌 王 .

Drug Repurposing in Oncology Therapy: Applications and Challenges

[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2026 , 28(7) : 832 -832-836 . DOI: 10.1009-0959.2026.090002

References

        [1] Armando RG, Gomez DLM, Gomez DE. New drugs are not enough-drug repositioning in oncology:an update[J].Intern J Oncol, 2020,56(3):651-684.

         [2]  Kaushik I, Ramachandran S, Prasad S, et al. Drug rechanneling:a novel paradigm for cancer treatment[J].Semin Cancer Biol, 2021,68:279-290.

         [3]  Coyle C. Repurposing medicines for the adjuvant treatment of cancer:an evaluation of aspirin and metformin[D].London: UCL, 2018.

         [4]  AL Khzem AH,Gomaa MS,Alturki MS,et al.Drug repurposing for cancer treatment:a comprehensive review[J].Int J Mol Sci, 2024,25(22):12441.

         [5]  王乐,王崇.接受非干扰素治疗的HCV相关肝癌患者的早期肿瘤复发[J].临床肝胆病杂志,2016,32(6):1211-1216.

         [6]  戎煜,安威,高鼎成,等.利用HSV-TK基因治疗肝癌的离体研究[J].中国应用生理学杂志,1998,14(3):268-271.

         [7]  Huang Peiju, Chiu Chunching, Hsiao Minhua, et al. Potential of antiviral drug oseltamivir for the treatment of liver cancer[J].Int J Oncol, 2021,59(6): 109.

         [8]  邵莎莉,庄喜兵,乔田奎.氟西汀通过p21相关通路增加顺铂对非小细胞肺癌细胞株的抗肿瘤作用[J].复旦学报(医学版),2023,50(1):48-56.

         [9]  DI Rosso ME, Sterle HA, Cremaschi GA, et al. Beneficial effect of fluoxetine and sertraline on chronic stress-induced tumor growth and cell dissemination in a mouse model of lymphoma: crucial role of antitumor immunity[J].Front Immunol, 2018,9:1341.

         [10] Li Bo, Elsten-Brown J, Li Miao, et al. Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis[J].Cell, 2025,188(14):3823-3842.

         [11] Bielecka AM, Obuchowicz E. Antidepressant drugs as a complementary therapeutic strategy in cancer[J].Exp Biol Med (Maywood), 2013,238(8):849-858.

         [12] 易琨.生物免疫调节剂在浅表性膀胱肿瘤治疗中的应用[J].中国处方药,2014,12(5):61-62.

         [13] Xu Li, Zhang Li, Hu Chang, et al. WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells[J].Int J Oncol, 2016,48(3):1175-1186.

         [14] Adornetto A, Laganà ML, Satriano A, et al. The antidepressant drug amitriptyline affects human SH-SY5Y neuroblastoma cell proliferation and modulates autophagy[J].Int J Mol Sci, 2024,25(19):10415.

         [15] 彭含含,骆玉霜.肺癌与肿瘤炎症微环境相关性的研究进展[J].临床个性化医学,2024,3(2):341-346.

         [16] 路遥,辛道,刘得恩,等.二甲双胍影响肿瘤免疫微环境的研究进展[J].肿瘤综合治疗电子杂志,2019,5(3):61-65.

         [17] Krishnamurthy N, Grimshaw AA, Axson SA, et al. Drug repurposing: a systematic review on root causes, barriers and facilitators[J].BMC Health Serv Res, 2022,22(1):970.

         [18] 黄娜娜,孙蓉.网络药理学与中成药再评价[J].中国药理学与毒理学杂志,2019,33(9): 653-659.

         [19] Talarico G, Orecchioni S, Dallaglio K, et al. Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells[J].Sci Rep, 2016,6(1):18673.

         [20] 代维娜, 张永红.医学网络分析方法研究药物抗胆汁淤积症的作用机制[C]//中国化学会,第十五届全国计算(机)化学学术会议论文集,上海:2019.

         [21] Tanoli Z, VäHä-koskela M, Aittokallio T. Artificial intelligence, machine learning, and drug repurposing in cancer[J].Expert Opin Drug Discov, 2021,16(9):977-989.

         [22] 程群,朱汉民,刘忠厚.所有的双膦酸盐都一样吗?[J].中国骨质疏松杂志,2010,16(5):369-376.

         [23] 刘灿,王峰,樊青霞.二甲双胍抗肿瘤治疗的临床研究进展[J].中国肿瘤临床,2018,45(20):1077-1080.

         [24] 兰聪,李婧雯,甘立霞.二甲双胍降低糖尿病患者肿瘤发病风险及机制的研究进展[J]. 肿瘤防治研究,2014,41(11):1241-1246.

         [25] Yu Xinning, Wu Huatao, WU Bingxuan, et al. Advances and challenges in drug repurposing in precision therapeutics of colorectal cancer[J].World J Gastrointest Oncol, 2025,17(7):107681.

         [26] 史婷婷,肖洪涛.氯喹在肿瘤中的应用研究进展[J].中国生化药物杂志,2016,36(5):24-27.

         [27] 董清.负载氯喹的重组高密度脂蛋白用于增强肿瘤免疫治疗[D].保定:河北大学,2022.

         [28] 盛艾娟,王小琪,孙李妍,等.研究参与者补偿权保障探析[J].中国医学伦理学,2024,37(5):507-513.

         [29] Wang Zhengguo, Zhang Liang, Zhao Wenjun. Definition and application of precision medicine[J].Chin J Traumatol, 2016,19(5): 249-250.

         [30] Liu Ruoqi, Wei Lai, Zhang Ping. A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data[J].Nat Mach Intell, 2021,3(1):68-75.

         [31] 甘枥元,郭超峰.人工智能深度学习技术在网络药理学领域的研究进展[J].医药前沿,2025,15(7):23-25.

         [32] 陈璐,何艳,徐芳,等.《涉及人的生命科学和医学研究伦理审查办法》对健康信息数据相关研究的新要求及审查要点[J].中国医学伦理学,2024,37(4):392-398.

Outlines

/

〈 〉